WO2013169977A3 - Controlled release solid dose form - Google Patents

Controlled release solid dose form Download PDF

Info

Publication number
WO2013169977A3
WO2013169977A3 PCT/US2013/040263 US2013040263W WO2013169977A3 WO 2013169977 A3 WO2013169977 A3 WO 2013169977A3 US 2013040263 W US2013040263 W US 2013040263W WO 2013169977 A3 WO2013169977 A3 WO 2013169977A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
release solid
dose form
active ingredient
solid dose
Prior art date
Application number
PCT/US2013/040263
Other languages
French (fr)
Other versions
WO2013169977A2 (en
Inventor
Christopher J. Sewall
William R. Blakemore
Bruno Leclercq
Original Assignee
Fmc Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corporation filed Critical Fmc Corporation
Priority to EP13788234.6A priority Critical patent/EP2846812A2/en
Publication of WO2013169977A2 publication Critical patent/WO2013169977A2/en
Publication of WO2013169977A3 publication Critical patent/WO2013169977A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to a controlled release solid dosage form comprising a controlled release modifier and an active ingredient comprising at least one of a pharmaceutical, veterinary, or nutraceutical active ingredient, wherein the controlled release modifier comprises lambda carrageenan from the taxonomic order Halymeniales. The present invention is also directed to ethanol resistant controlled release solid dosage forms and methods for reducing the ethanol sensitivity of an active ingredient in a controlled release solid dose form.
PCT/US2013/040263 2012-05-10 2013-05-09 Controlled release solid dose form WO2013169977A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13788234.6A EP2846812A2 (en) 2012-05-10 2013-05-09 Controlled release solid dose form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645409P 2012-05-10 2012-05-10
US61/645,409 2012-05-10

Publications (2)

Publication Number Publication Date
WO2013169977A2 WO2013169977A2 (en) 2013-11-14
WO2013169977A3 true WO2013169977A3 (en) 2014-01-09

Family

ID=49549099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/040263 WO2013169977A2 (en) 2012-05-10 2013-05-09 Controlled release solid dose form

Country Status (3)

Country Link
US (1) US20130303632A1 (en)
EP (1) EP2846812A2 (en)
WO (1) WO2013169977A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355272B1 (en) * 1997-10-29 2002-03-12 Eurand International S.P.A. Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions
WO2010012490A1 (en) * 2008-08-01 2010-02-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Quetiapine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085304A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
MY161550A (en) * 2008-10-27 2017-04-28 Alza Corp Extended release oral acetaminophen/tramadol dosage form
EP2373319B1 (en) * 2009-01-05 2013-07-31 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
JP5907989B2 (en) * 2010-12-17 2016-04-26 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ Liquid formulation comprising lambda carrageenan derived from protein and isonohana

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355272B1 (en) * 1997-10-29 2002-03-12 Eurand International S.P.A. Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions
WO2010012490A1 (en) * 2008-08-01 2010-02-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Quetiapine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FENORADOSOA T.A. ET AL.: "Highly sulphated galactan from Halymenia durvillei (Halymeniales, Rhodophyta), a red seaweed of Madagascar marine coasts.", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 45, no. 2, 2009, HTTP://WWW.SCIENCEDIRECT.COM/SCIENCE/ARTICLE/PII/S0141813009000841, XP026196867 *

Also Published As

Publication number Publication date
WO2013169977A2 (en) 2013-11-14
EP2846812A2 (en) 2015-03-18
US20130303632A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
WO2012174158A3 (en) Administration of benzodiazepine
EA201200937A1 (en) SOLID MEDICINE FORM TICAGRELOR
UA106634C2 (en) Solid pharmaceutical dosage form
MX356111B (en) Immediate release, abuse deterrent pharmaceutical compositions.
IN2015DN03984A (en)
ES2425315R1 (en) Pharmaceutical composition and its use to prepare a medicine for the symptomatic treatment of a respiratory disease or condition
AU2012347200A8 (en) Tablet capable of combatting misuse by injection
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
CR20110704A (en) COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
EA201400737A1 (en) DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE
PH12015500823A1 (en) Modified release formulations for oprozomib
WO2012007846A3 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
MX363699B (en) Co-micronisation product comprising ulipristal acetate.
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
EA201200485A1 (en) ORAL FALLING PHARMACEUTICAL DRUG FORM CONTAINING AIPIPRAZOL
PH12016501039A1 (en) Pharmaceutical dosage forms
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
BR112017019364A2 (en) solid dispersions
ZA201505084B (en) Monolithic dosage form for the modified release of an active ingredient combination
MX2014006201A (en) Imatinib solid dosage forms reconstituted just before use.
WO2014065640A3 (en) Composition for treating or preventing inflammatory diseases containing myagropsis myagroides extract or fraction thereof as active ingredient
WO2013169977A3 (en) Controlled release solid dose form

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2013788234

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13788234

Country of ref document: EP

Kind code of ref document: A2